Hybrid lipid core chitosan-TPGS shell nanocomposites as a promising integrated nanoplatform for enhanced oral delivery of sulpiride in depressive disorder therapy

• Published in: International journal of biological macromolecules Vol. 188; pp. 432 - 449
• Main Authors: Mohyeldin, Salma M., Samy, Wael M., Ragab, Doaa, Abdelmonsif, Doaa A., Aly, Rania G., Elgindy, Nazik A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.10.2021
• Subjects: Administration, Oral; Caco-2 Cells; Chitosan - chemistry; Chitosan - pharmacology; Chitosan-TPGS; Depression; Depressive Disorder - drug therapy; Humans; Lipids - chemistry; Lipids - pharmacology; Nanocomposites - chemistry; Nanohybrids; Oral bioavailability; Sulpiride; Sulpiride - chemistry; Sulpiride - pharmacology; Toxicity; Vitamin E - chemistry; Vitamin E - pharmacology; Depression; Oral bioavailability; Nanohybrids; Chitosan-TPGS; Toxicity; Sulpiride
• ISSN: 0141-8130; 1879-0003
• DOI: 10.1016/j.ijbiomac.2021.08.035

Sulpiride (SUL), a benzamide derivative, acts as a multitarget drug with extensive biological properties. However, being a P-glycoprotein efflux substrate with a limited oral bioavailability imposes a challenge to its clinical efficacy. The current research explores the impact of tailored hybrid lipid-polysaccharide nanocomposites in augmenting the biological performance of SUL. Chitosan-graft-tocopherol polyethylene glycol 1000 succinate (TPGS) copolymers were synthesized and integrated as a polysaccharide shell into a SUL-loaded lipid nanocore. The optimized nanohybrids revealed a nanocore-shell structure with 110.1 nm particle size, 23.7 mV zeta potential, 85.42% encapsulation efficiency, a pH-dependent-release profile, and an acceptable mucoadhesive tendency. Employing TPGS into the chitosan backbone alleviated the cellular internalization of nanohybrids into the Caco-2 intestinal cells and hence increased the intestinal permeation and the oral bioavailability of SUL by 3.3, and 8.7-folds, respectively. Reserpine-induced depression rat model confirmed the superior antidepressant activity of nanohybrids, compared with free SUL and a marketed product. The nanohybrids exhibited 1.87- and 1.47-folds enhancement in both serotonin and dopamine levels, respectively. Additionally, nanohybrids were shown to attenuate brain oxidative stress state and SUL irritant effect on different body tissues. Overall, the newly tailored nanohybrids pave the way for an advance in the field of oral drug delivery. •Chitosan-TPGS (CT) conjugates with different degrees of grafting were synthesized.•Lipospheres/CT nanohybrids of sulpiride were prepared for depression management.•CT nanohybrids enhanced Caco-2 cellular uptake and sulpiride oral bioavailability.•The optimized nanohybrids succeeded to increase the serotonin and dopamine levels.•Nanohybrids also reduced oxidative stress in brain tissue with high safety profile.